Covid isnt our nearest path to revenue , unless

Covid isnt our nearest path to revenue , unless we consider the small amount coming in from the Philippines. going forward, IMO, we need to stop all efforts in chasing Covid critical and focus in on the future of this company..Cancer, NASH, autoimmune diseases. we need to focus our resources, both human and capital on who this company is going to be. In retrospect , chasing covid got us off track on the drug's mission as Dr. Kelly sees it. Add to that only 8m in cash and a loan environment that will be close to impossible to navigate with a share price hovering around 70 cents...